Secukinumab (Cosentyx)
Fully human IgG1-kappa monoclonal antibody targeting IL-17A. Approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA, and hidradenitis suppurativa. Loading 300 mg SC at weeks 0, 1, 2, 3, 4 then 300 mg monthly. Biphasic PK with terminal half-life ~27 days. SC bioavailability ~73%. Monitor for inflammatory bowel disease exacerbation and candidiasis.
Projected serum levels — 300 mg, custom (shown daily)
Maintenance schedule: 300 mg custom (shown daily) (subcutaneous).
Loading schedule: 900 mg on day 1, then 300 mg custom (shown daily) — reaching therapeutic levels sooner.
Modeled steady state after ~108 days: peak ≈ 8.2k mg, trough ≈ 8.2k mg body load. Population-based estimate over 121 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Biologic
- Route modeled
- Subcutaneous
- Model confidence
- inferred
- Half-life
- 27 days
- Common dose
- 300 mg
- Suggested maximum
- 300 mg/day
- Reference dose range
- 150–300 mg (single dose)
- Suggested cadence
- custom (shown daily)
- Validated against
- 150 mg sc — Cmax 14 mg/L at 144 h
Research behind this entry
-
Clinical pharmacokinetics and pharmacodynamics of secukinumab
Comprehensive PK/PD review: biphasic disposition, ~27-day terminal half-life, SC bioavailability ~73%, and exposure-response relationship.
-
Secukinumab in plaque psoriasis - results of two phase 3 trials (ERASURE and FIXTURE)
Pivotal ERASURE and FIXTURE trials establishing secukinumab 300 mg superior to placebo and etanercept for plaque psoriasis.
2 published studies referenced in the app, each with a plain-language summary.